Pfizer Reports Infection Rates for Elrexfio Patients Versus Investigator’s Choice
Grade 3+ infections occurred in 27.5% of Elrexfio patients versus 18.1% with investigator’s choice; grade 5 infections were 0.8% versus 1.6%.
Grade 3+ infections occurred in 27.5% of Elrexfio patients versus 18.1% with investigator’s choice; grade 5 infections were 0.8% versus 1.6%.